Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 8/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30751856 | 1.00 | KCNJ1 (0.45) | KCNJ1KDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL20168106 | 0.85 | KCNJ1 (0.42) | KCNJ1KDM4EALDH1A1MAPK1RECQL | |
| SCHEMBL30751829 | 0.85 | KCNJ1 (0.42) | KCNJ1KDM4EALDH1A1MAPK1RECQL | |
| SCHEMBL30751837 | 0.81 | RECQL (0.47) | KCNJ1ALDH1A1MAPK1SMN1; SMN2TSHR | |
| SCHEMBL20168150 | 0.81 | RECQL (0.47) | KCNJ1ALDH1A1MAPK1SMN1; SMN2TSHR | |
| SCHEMBL30445137 | 0.80 | KCNJ1 (0.43) | KCNJ1KDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL20574896 | 0.80 | KCNJ1 (0.43) | KCNJ1KDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL20574272 | 0.77 | KCNJ1 (0.42) | KCNJ1KDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL30445102 | 0.77 | KCNJ1 (0.42) | KCNJ1KDM4EALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL20168541 | 0.77 | KCNJ1 (0.39) | KCNJ1KDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110139862-B | Substituted bicyclic heterocyclic derivatives useful as ROMK channel inhibitors | 百时美施贵宝公司 | 2024-01-16 | — | — | CN | disclosed |
| EP-3535258-B1 | SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-11-24 | — | — | EP | disclosed |
| US-10723723-B2 | Substituted bicycle heterocyclic derivatives useful as ROMK channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-28 | — | — | US | disclosed |
| US-10723723-B2 | Substituted bicycle heterocyclic derivatives useful as ROMK channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190248769-A1 | SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-15 | — | — | US | disclosed |
| US-20190248769-A1 | SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-15 | — | — | US | disclosed |
| WO-2018093569-A1 | SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723723-B2 | Substituted bicycle heterocyclic derivatives useful as ROMK channel inhibitors | KCNB1, CACNA1E, GRK1 | KCNJ1 85/4885KDM4E 3724/4885ALDH1A1 2047/4885 |
| US-20190248769-A1 | SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS | KCNB1, CACNA1E, GRK1 | KCNJ1 85/4885KDM4E 3724/4885ALDH1A1 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.